Last reviewed · How we verify
NCT06933355: SGL-TX-MR
Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension
Phase 4 trial testing JARDIANCE 25mg in Kidney Transplantation Recipients in 8 participants. Participants enrolled and being followed up; not accepting new ones.
1 April 2026
Quick facts
| Lead sponsor | Odense University Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 27 March 2025 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- JARDIANCE 25mg — full drug profile →
- Placebo
Conditions studied
- Kidney Transplantation Recipients — all drugs for Kidney Transplantation Recipients →
- Magnetic Resonance Imaging (MRI) — all drugs for Magnetic Resonance Imaging (MRI) →
- Sodium-Glucose Transporter 2 Inhibitors — all drugs for Sodium-Glucose Transporter 2 Inhibitors →
- Non-Diabetic Patients — all drugs for Non-Diabetic Patients →
Sponsor
Odense University Hospital
Who can join
18 and older, any sex, with Kidney Transplantation Recipients or Magnetic Resonance Imaging (MRI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to investigate if a single dose of oral SGLT2i, (50 mg Jardiance) will change oxygen tension in the kidney transplant. The main questions it aims to answer are: * Does a single dose of oral SGLT2i (50 mg Jardiance) change oxygen tension in the kidney transplant cortex and medulla, estimated by magnetic resonance imaging? * Does a single dose of oral SGLT2i (50 mg Jardiance) change kidney transplant cortical and medullary perfusion? * Does a single dose of oral SGLT2i (50 mg Jardiance) change kidney transplant artery blood flow? * Does a single dose of oral SGLT2i (50 mg Jardiance) change blood glucoses, blood pressure and heart rate? Researchers will compare a single dose of oral SGLT2i (50 mg Jardiance) to a placebo (a look-alike substance that contains no drug) to see if a single dose of oral SGLT2i (50 mg Jardiance) changes oxygen tension in the kidney transplant. Kidney transplant recipients with out diabetes will: * Meet for two intervention days. * A single dose of oral SGLT2i (50 mg Jardiance) or placebo will be given in random order, separated by at least 2 week washout period, the experiment will be repeated with the opposite treatment. * Kidney cortex oxygenation, and blood flow in different compartments of the kidney transplant, is estimated by blood-oxygen-dependent level magnetic resonance imaging (BOLD-MRI). Patients are evaluated by routine clinical examination and routine biochemical measures for kidney transplant patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
SGL-TX-MR-study protocol acute effects of SGLT2 inhibitor on kidney allograft oxygen tension, a randomized, double-blind, placebo controlled crossover trial.
Lange LB, Bistrup C. · · 2025 · PMID 41462489 · DOI 10.1186/s13063-025-09244-4
Verify or expand the search:
- PubMed search for NCT06933355
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of JARDIANCE 25mg
Trials testing the same drug.
- NCT02848833 — JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus · completed
Other recruiting trials for Kidney Transplantation Recipients
Currently open trials in the same condition.
- NCT07415421 — Parathyroidectomy After Kidney Transplantation · NA · recruiting
- NCT07143773 — SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients · Phase 4 · recruiting
- NCT07356388 — FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan · Phase 3 · active not recruiting
- NCT06848816 — Duration of Antibiotic Therapy in Acute Kidney Graft Pyelonephritis (AGPN): Effect on the Risk of Recurrence · active not recruiting
Other Odense University Hospital trials
Trials by the same sponsor.
- NCT07163091 — Bracing After Ankle Fracture · NA · not yet recruiting
- NCT07521696 — Physical Recovery During Bracing After Ankle Fracture (Re-BAF) · NA · not yet recruiting
- NCT07466212 — QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy · not yet recruiting
- NCT07191379 — Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma · Phase 4 · not yet recruiting
- NCT07170085 — Positioning of Children With Acute Respiratory Insufficiency · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06933355 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Odense University Hospital
- Last refreshed: 31 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06933355.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing